Phase II Study of Camrelizumab with Chemoradiotherapy for Advanced Esophageal Squamous Cell Carcinoma in Patients Aged 18 to 75

What this Trial Is About

Researchers are evaluating the combination of camrelizumab with chemoradiotherapy and chemotherapy in patients with advanced esophageal cancer who have not received any prior systemic antitumor treatment. This prospective single-arm exploratory clinical study aims to assess the safety and effectiveness of these treatments in patients with esophageal squamous cell carcinoma at advanced stages. The study is sponsored by Fujian Cancer Hospital and focuses on advanced first-line treatment for esophageal cancer. Participants will receive camrelizumab 200 mg through intravenous drip every three weeks, along with chemotherapy drugs including paclitaxel at 150 mgm2 every three weeks and a platinum-based drug such as cisplatin, carboplatin, or nedaplatin. Radiotherapy will be administered at a dose of 5040 cGy over 28 fractions. After 2 to 3 cycles of chemotherapy, patients who show partial response or stable disease will receive local radiotherapy as part of the treatment plan. During the study, participants will be monitored with evaluations of tumor response and safety assessments. Researchers will measure the objective response rate over three years as the primary outcome, along with overall survival and progression-free survival during the same period. Patients will be followed regularly for treatment effects and side effects, and the total duration of participation may extend up to three years to capture long-term outcomes.

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.